Literature DB >> 22292623

Role of hypercholesterolemia in prostate cancer--case control study from Manipal Teaching Hospital Pokhara, Nepal.

Ankush Mittal1, Brijesh Sathian, Nishida Chandrasekharan, Akshay Lekhi, Shambu Kumar Yadav.   

Abstract

OBJECTIVE: The objective of this study was to appraise the role of hypercholesterolemia in prostate cancer among residents of Pokhara valley, Nepal.
MATERIALS AND METHODS: A hospital based retrospective study was carried out using data retrieved from the register maintained in the Department of Biochemistry of the Manipal Teaching Hospital, Pokhara, Nepal between 1st January, 2009, and 31st December, 2010. Descriptive statistics and testing of hypothesis were used for the analysis using EPI INFO and SPSS 16 software.
RESULTS: Of the 1,200 subjects, 600 were cancer patients and 600 were controls. In the 600 cases, the mean age was 69.4 ± SD 10.2 years, with a preponderance in age group distribution between 65-69 years. The mean value of prostate specific antigen in cases (14.54 ± SD 12.32 ng/ml) was markedly raised as compared to controls (1 ± SD 0.52 ng/ml) (p=0.0001). The mean value of total cholesterol levels (237.9 ± 31.2 mg/dl) was also increased along with raised PSA levels in cases when compared with controls (184 ± 33.8 mg/dl) (p=0.0001). The percentage of cases with HDL normal limits (40 to 60 mg/dl) was 72% which did not show much variation when compared to 79% in controls. However, the percentage of cases with LDL borderline high (150-190 mg/dl) was 30% ands markedly increased when compared to the 5% in controls.
CONCLUSION: The identification of cholesterol as a vital module in signal transduction events in prostate cancer cells has not only bestowed us with new mechanistic insights but has also opened up new avenues for prostate cancer chemotherapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22292623

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  5 in total

Review 1.  The Impact of Lifestyle on Prostate Cancer: A Road to the Discovery of New Biomarkers.

Authors:  Catarina Leitão; Bárbara Matos; Fátima Roque; Maria Teresa Herdeiro; Margarida Fardilha
Journal:  J Clin Med       Date:  2022-05-22       Impact factor: 4.964

2.  Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling.

Authors:  Xiangyan Li; Yi-Ting Chen; Peizhen Hu; Wen-Chin Huang
Journal:  Mol Cancer Ther       Date:  2014-02-03       Impact factor: 6.261

3.  Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC).

Authors:  Yifan Kong; Lijun Cheng; Fengyi Mao; Zhuangzhuang Zhang; Yanquan Zhang; Elia Farah; Jacob Bosler; Yunfeng Bai; Nihal Ahmad; Shihuan Kuang; Lang Li; Xiaoqi Liu
Journal:  J Biol Chem       Date:  2018-08-08       Impact factor: 5.157

Review 4.  High-density lipoprotein and prostate cancer: an overview.

Authors:  Kazuhiko Kotani; Yoshitaka Sekine; Shizukiyo Ishikawa; Imoh Z Ikpot; Kazuhiro Suzuki; Alan T Remaley
Journal:  J Epidemiol       Date:  2013-08-27       Impact factor: 3.211

5.  Simvastatin enhances irinotecan-induced apoptosis in prostate cancer via inhibition of MCL-1.

Authors:  Mohammad A Y Alqudah; Hebah T Mansour; Nizar Mhaidat
Journal:  Saudi Pharm J       Date:  2017-12-13       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.